Abstract:Introduction: Human tumors, including gastric cancer, frequently express high levels of epidermal growth factor receptors (EGFRs), which are associated with a poor prognosis. Targeted delivery of anticancer drugs to cancerous tissues shows potential in sparing unaffected tissues. However, it has been a major challenge for drug penetration in solid tumor tissues due to the complicated tumor microenvironment. Chemotherapy employing paclitaxel (PTX) is widely used for treating various kinds of cancer including gastric cancer.Methods: Recombinant protein anti-EGFR-iRGD consisting of an anti-EGFR VHH (the variable domain from the heavy chain of the antibody) fused to iRGD, a tumor-specific binding peptide with high permeability were expressed in E. coli BL21 (DE3) and purified by nickel-nitrilotriacetic acid affinity chromatography. We use tumor cell lines (2D), multicellular spheroids (3D), and mice to analyze the antitumor activity of recombinant protein. To investigate the ability of anti-EGFR-iRGD to improve other drugs (e.g. PTX) penetrating into tumor, we used multicellular spheroids and mice.Results: We have successfully constructed a recombinant protein named anti-EGFR-iRGD, a dual target of EGFR and integrin and high permeable protein. It could spread extensively throughout both the multicellular spheroids and the tumor mass. The recombinant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor cell lines (2D), multicellular spheroids (3D), and mice. Moreover, we demonstrated the therapeutic efficacy of PTX combined with anti-EGFR-iRGD on monolayer cells (2D), multicellular spheroids (3D) and tumor-bearing mice for the first time.Conclusion: Our results provide impetus for further studies for potentially using iRGD based fusion protein anti-EGFR-iRGD with standard cytotoxic treatment regimens for enhancing therapy of gastric cancer patients.Figure: P-014 Introduction: Human tumors, including gastric cancer, frequently express high levels of epidermal growth factor receptors (EGFRs), which are associated with a poor prognosis. Targeted delivery of anticancer drugs to cancerous tissues shows potential in sparing unaffected tissues. However, it has been a major challenge for drug penetration in solid tumor tissues due to the complicated tumor microenvironment. Chemotherapy employing paclitaxel (PTX) is widely used for treating various kinds of cancer including gastric cancer. Methods: Recombinant protein anti-EGFR-iRGD consisting of an anti-EGFR VHH (the variable domain from the heavy chain of the antibody) fused to iRGD, a tumor-specific binding peptide with high permeability were expressed in E. coli BL21 (DE3) and purified by nickel-nitrilotriacetic acid affinity chromatography. We use tumor cell lines (2D), multicellular spheroids (3D), and mice to analyze the antitumor activity of recombinant protein. To investigate the ability of anti-EGFR-iRGD to improve other drugs (e.g. PTX) penetrating into tumor, we used multicellular spheroids and mice. Results: We have successfully constructed a recombinant protein named anti-EGFR-iRGD, a dual target of EGFR and integrin and high permeable protein. It could spread extensively throughout both the multicellular spheroids and the tumor mass. The recombinant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor cell lines (2D), multicellular spheroids (3D), and mice. Moreover, we demonstrated the therapeutic efficacy of PTX combined with anti-EGFR-iRGD on monolayer cells (2D), multicellular spheroids (3D) and tumor-bearing mice for the first time. Conclusion: Our results provide impetus for further studies for potentially using iRGD based fusion protein anti-EGFR-iRGD with standard cytotoxic treatment regimens for enhancing therapy of gastric cancer patients. Figure: P-014

Rg17pe38, a Novel Immunotoxin Target to Gastric Cancer with Overexpressed CCK-2R.

A novel immunotoxin - rCCK8PE38 targeting of CCK-R overexpressed colon cancers.

Expression, Purification and Characterization of Recombinant Toxins Consisting of Truncated Gastrin 17 and Pseudomonas Exotoxin

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

Pseudomonas Exotoxin A-Based Immunotherapy Targeting CCK2R-Expressing Colorectal Malignancies: an in Vitro and in Vivo Evaluation.

Characterization of Recombinant Toxin rCCK96-104PE38 Targeting Colon Cancer

Downregulation of CCKBR Expression Inhibits the Proliferation of Gastric Cancer Cells, Revealing a Potential Target for Immunotoxin Therapy

An Efficient Scheme for Purification of a Novel Recombinant Immunotoxin, Rcck8pe38, for Anti-Tumour Experiments.

Abstract A20: A Tumor-Penetrating Recombinant Protein Anti-Egfr-irgd Enhance Efficacy of Antigen-Specific CTL in Gastric Cancer in Vivo

CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin

P-014A Tumor-penetrating Recombinant Protein Anti-Egfr-irgd Enhance Efficacy of Paclitaxel in 3D Multicellular Spheroids and Gastric Cancer in Vivo

Both Glycine-Extended Gastrin (G-Gly) and Gastrin (G17) Stimulated COX-2 Expression Via CCK-B Receptor in Intestinal Epithelial Cells

[Preliminary Screening and Identification of a Peptide That Binds Specifically to Gastric Cancers Cells with High Metastasis to Peritoneum].

HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity

The Construction of Anti-EGFR Single Chain Variable Fragment Fused with Gelonin Toxin Prokaryotic Expressing Plasmid and the Study of Its Anti-tumor Effects

Specific Targeting of the Vasculature of Gastric Cancer by a New Tumor-Homing Peptide CGNSNPKSC.

Shiga-like Toxin I Exerts Specific and Potent Anti-Tumour Efficacy Against Gastric Cancer Cell Proliferation when Driven by Tumour-Preferential Frizzled-7 Promoter.

Investigation of a Plasmid Containing a Novel Immunotoxin VEGF165‐PE38 Gene for Antiangiogenic Therapy in a Malignant Glioma Model

A Tumor-Penetrating Recombinant Protein Anti-Egfr-irgd to Enchance Efficacy of Paclitaxel in 3D Multicellular Spheroids and Gastric Cancer in Vivo.

Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo

Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL